BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28743369)

  • 21. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
    Ataseven B; du Bois A; Reinthaller A; Traut A; Heitz F; Aust S; Prader S; Polterauer S; Harter P; Grimm C
    Gynecol Oncol; 2015 Sep; 138(3):560-5. PubMed ID: 26163893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
    Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
    J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.
    von Gruenigen VE; Huang HQ; Gil KM; Gibbons HE; Monk BJ; Rose PG; Armstrong DK; Cella D; Wenzel L
    Cancer; 2009 Oct; 115(20):4857-64. PubMed ID: 19691091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.
    Luo Y; Kim HS; Kim M; Lee M; Song YS
    J Gynecol Oncol; 2017 May; 28(3):e36. PubMed ID: 28382799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
    Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
    Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer.
    Thavaramara T; Phaloprakarn C; Tangjitgamol S; Manusirivithaya S
    J Med Assoc Thai; 2011 Jul; 94(7):871-7. PubMed ID: 21774296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO.
    Klar M; Hasenburg A; Hasanov M; Hilpert F; Meier W; Pfisterer J; Pujade-Lauraine E; Herrstedt J; Reuss A; du Bois A
    Eur J Cancer; 2016 Oct; 66():114-24. PubMed ID: 27561452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
    Horowitz NS; Larry Maxwell G; Miller A; Hamilton CA; Rungruang B; Rodriguez N; Richard SD; Krivak TC; Fowler JM; Mutch DG; Van Le L; Lee RB; Argenta P; Bender D; Tewari KS; Gershenson D; Java JJ; Bookman MA
    Gynecol Oncol; 2018 Jan; 148(1):49-55. PubMed ID: 29174555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
    Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
    Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-dense approaches to ovarian cancer treatment.
    Katsumata N
    Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
    Osann K; Wenzel L; McKinney C; Wagner L; Cella D; Fulci G; Scroggins MJ; Lankes HA; Wang V; Nephew KP; Maxwell GL; Mok SC; Conrads TP; Miller A; Birrer M
    Gynecol Oncol; 2023 Apr; 171():151-158. PubMed ID: 36905875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials.
    Hui D; Darke AK; Guthrie KA; Subbiah IM; Unger JM; Hershman DL; Krouse RS; Bakitas M; O'Rourke MA
    JCO Oncol Pract; 2022 Apr; 18(4):e442-e451. PubMed ID: 34606328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
    Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
    BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
    So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
    Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182.
    Rodriguez N; Miller A; Richard SD; Rungruang B; Hamilton CA; Bookman MA; Maxwell GL; Horowitz NS; Krivak TC
    Gynecol Oncol; 2013 Sep; 130(3):487-92. PubMed ID: 23791702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.